Corporate Overview

We are a global medical technology company focused on the development and commercialization of our proprietary Vapotherm high velocity therapy, a tool used to treat patients of all ages suffering from respiratory distress. High velocity therapy delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Our Precision Flow systems, which deliver high velocity therapy, are clinically validated alternatives to, and address many limitations of, the current standard of care for the treatment of respiratory distress in a hospital setting. More than 4 million patients have been treated with our Precision Flow systems, and we have a global installed base of over 37,000 capital units. 

Latest News
06/17/2024

Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of...

READ MORE

05/09/2024

Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2024 financial results and related highlights. First Quarter 2024 Financial Results and Related...

READ MORE

03/20/2024

Partnership enables Vapotherm to build a robust and secure solution 80% faster than the standard development timeline to meet data visualization and device management goals for HVT® 2.0 and...

READ MORE

VIEW ALL NEWS

Latest Presentation

05/10/2024

Vapotherm Company Overview

VIEW ALL PRESENTATIONS

Latest Events
No events to display

VIEW ALL EVENTS

Latest Quarterly Reports